The neurotology biopharma Otonomy (Nasdaq:OTIC) has announced that the brain-derived neurotrophic factor agonist OTO-413 resulted in clinically meaningful improvement in a Phase 2a trial focused on subjects with hearing loss. In the randomized, double-blind, placebo-controlled study, subjects received a single intratympanic injection of 0.3 mg of OTO-413. Subjects in the study had 30 evaluable subjects…
Otonomy expands Phase 1/2 hearing loss clinical trial
Neurotology drug developer Otonomy (NSDQ:OTIC) is expanding a Phase 1/2 trial of OTO-413 in patients with difficulty with speech-in-noise tests. In the trial, clinical investigators administer the drug as a single intratympanic injection. The company said that OTO-413 showed promise in improving hearing in a dose escalation efficacy cohort. The randomized, double-blind, placebo-controlled Phase 1/2…